Josiane Mourão Dias

Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC

Byoung Chul Cho, Shun Lu, Enriqueta Felip et al. · New England Journal of Medicine · 2024 · 375 citations · Full text

Medicine, Oncology, Pharmacology +14

Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions

Caicun Zhou, Kejing Tang, Byoung Chul Cho et al. · New England Journal of Medicine · 2023 · 347 citations

Medicine, Oncology, Pharmacology +14

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 210 citations · Full text

Medicine, Oncology, Pharmacology +16

CONSENSUS REPORT: Recognizing non‐melanoma skin cancer, including actinic keratosis, as an occupational disease – A Call to Action

Swen Malte John, Myrto Trakatelli, Ronette Gehring et al. · Journal of the European Academy of Dermatology and Venereology · 2016 · 86 citations · Full text

Medicine, Dermatology, Oncology +17

Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

Byoung Chul Cho, Jong Seok Lee, Yi‐Long Wu et al. · Journal of Thoracic Oncology · 2023 · 85 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12